Phase 2
Completed N=12
Cangrelor Prasugrel Transition Study
Source: ClinicalTrials.gov NCT01852019 ↗Enrolled (actual)
12
Serious AEs
0.0%
Results posted
May 2015
Primary outcomePrimary: Extent of Preservation of Inhibitory Effect After Transition From Cangrelor to Prasugrel Compared With Effect Observed With Prasugrel Alone (Reference Timepoint) — 1.0; 2.8; 5.0; 27 % aggregation
Summary
To demonstrate that patients treated with cangrelor can be directly switched to oral prasugrel and that patients treated with prasugrel can be switched to cangrelor without a significant decrease in the extent of inhibition of platelet aggregation.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Extent of Preservation of Inhibitory Effect After Transition From Cangrelor to Prasugrel Compared With Effect Observed With Prasugrel Alone (Reference Timepoint) |
7.7; 41; 74; 91; 82; 151 | — |
| PRIMARY Extent of Preservation of Inhibitory Effect of Cangrelor Treatment After Prasugrel, Compared to Treatment With Cangrelor Alone |
6.3; 8.3; 4.7; 13 | — |
| SECONDARY Extent of Preservation of Inhibitory Effect After Transition From Cangrelor to Prasugrel Compared With Effect Observed With Prasugrel Alone (Reference Timepoint) |
7.7; 41; 74; 91; 82; 151 | — |
| SECONDARY Extent of Preservation of Inhibitory Effect of Cangrelor Treatment After Prasugrel, Compared to Treatment With Cangrelor Alone |
6.3; 8.3; 4.7; 13 | — |
| SECONDARY Bleeding Events in Accordance With the GUSTO Scale |
1; 0; 0; 0; 0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- greater than / equal to 18 and less than 75 years of age
- stable coronary artery disease defined by the following criteria
- Previous myocardial infarction defined by admission to the hospital with elevation of markers of injury or the presence of pathologic Q waves on at least 2 contiguous electrocardiogram (ECG) leads.
OR
- Previous revascularization by percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).
AND
- Treatment with aspirin (ASA) 81 mg daily.
Data sourced from ClinicalTrials.gov (NCT01852019). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.